ERBB2 and breast carcinoma: Datopotamab deruxtecan (Dato-DXd), a TROP2-targeted ADC with a topoisomerase I payload, is undergoing head-to-head phase III trials versus chemotherapy in both triple-negative and hormone receptor-positive/HER2-negative breast cancer [170, 171].